In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

Lusvertikimab achieved statistical significance on the primary and secondary endpoints in moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of ...

France-based OSE Immunotherapeutics’ (OSE) Phase II CoTikiS study of lusvertikimab has met primary and secondary endpoints, showing high rates of clinical and endoscopic remission after ten ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Pr. Walter Reinisch, Director of the IBD Study Group at the Medical University of Vienna, Department of Internal Medicine, Vienna, Austria, commented: “Lusvertikimab has been shown to significantly ...

Using Cellectis' TALEN ® gene editing technology, we developed 'Smart CAR T cells' with the ability to express a ...